Live Oak Health Sciences Fund (LOGSX) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Live Oak Health Sciences Fund (LOGSX) Financial Services Profile

Live Oak Health Sciences Fund (LOGSX) strategically invests in healthcare and life sciences companies, focusing on equity investments to leverage growth potential in a sector characterized by innovation and resilience, particularly during economic downturns.

What Is the Investment Thesis for LOGSX?

The investment thesis for Live Oak Health Sciences Fund (LOGSX) revolves around its strategic focus on the healthcare sector, which is projected to grow significantly due to increasing demand for medical innovations and an aging population. With a market capitalization of $54.6M, the fund is well-positioned to leverage growth opportunities in pharmaceuticals and biotechnology, sectors expected to expand at a CAGR of approximately 7% over the next five years. Key value drivers include the fund's disciplined investment approach, with at least 80% of assets dedicated to equities in health sciences, which provides exposure to high-growth companies. Additionally, the fund's flexibility to invest in foreign equities and REITs enhances its diversification, potentially mitigating risks associated with the U.S. market. However, risks such as regulatory changes and clinical trial outcomes could impact the performance of the underlying investments. Investors should monitor these factors closely as they evaluate the fund's potential.

Based on FMP financials and quantitative analysis

LOGSX Key Highlights

Market capitalization of $54.6M reflects a focused investment strategy in the healthcare sector.

• Beta of 0.46 indicates lower volatility compared to the broader market, suggesting a defensive investment profile.
• No dividend yield, aligning with the growth-oriented focus of the fund.
• Minimum of 80% of net assets dedicated to equity investments in health sciences, ensuring sector-specific exposure.
• Flexibility to include equity REITs and foreign shares enhances diversification and potential returns.

Who Are LOGSX's Competitors?

LOGSX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are LOGSX's Key Strengths?

Focused investment strategy on a high-growth sector.

• Strong research capabilities enhance investment selection.
• Established presence in the asset management industry.
• Defensive nature of healthcare investments mitigates volatility.

What Are LOGSX's Weaknesses?

No dividend yield may deter income-focused investors.

• Limited international exposure could restrict growth opportunities.
• Concentration in healthcare may increase sector-specific risks.
• Smaller market cap may limit investment appeal to larger institutions.

What Could Drive LOGSX Stock Higher?

LOGSX catalyst: Continued advancements in biotechnology and pharmaceuticals are expected to drive growth in the healthcare sector.

• The fund's strategy of investing at least 80% of net assets in health sciences provides a solid foundation for capital appreciation.
• The increasing demand for telehealth solutions is creating new investment opportunities within the healthcare landscape.
• Potential regulatory changes may impact the healthcare sector, presenting both risks and opportunities for the fund.
• The aging population is driving demand for innovative healthcare solutions, benefiting the fund's investment focus.

What Are the Key Risks for LOGSX?

Regulatory changes could significantly impact the performance of healthcare investments.

• Clinical trial outcomes remain a critical risk factor for pharmaceutical and biotech investments.
• Economic downturns may lead to reduced healthcare spending, affecting the fund's performance.
• Increased competition in the asset management sector could pressure fees and margins.
• Concentration in healthcare may expose the fund to sector-specific risks.

What Are the Growth Opportunities for LOGSX?

• Live Oak Health Sciences Fund (LOGSX) can capitalize on this trend by investing in leading pharmaceutical companies that are developing breakthrough treatments. The fund's strategy to focus on U.S. firms positions it well to benefit from the robust pipeline of drugs currently in development, which is expected to drive revenue growth over the next five years.
• Growth opportunity 2: The biotechnology sector is expected to grow at a CAGR of 7% through 2025, fueled by advancements in gene therapy and personalized medicine. LOGSX's investment strategy allows it to target high-potential biotech firms, which are at the forefront of these innovations. By investing in companies that are developing cutting-edge therapies, the fund can leverage the growth potential of this rapidly evolving market.
• LOGSX can enhance its portfolio by investing in companies that specialize in innovative medical devices, which are crucial for improving patient outcomes and reducing healthcare costs. This sector's growth trajectory presents a significant opportunity for the fund to achieve substantial returns.
• Growth opportunity 4: The telehealth market has seen exponential growth, projected to reach $459 billion by 2030, as healthcare providers increasingly adopt digital solutions. LOGSX can benefit from investing in companies that are leading this transformation, providing remote healthcare services and solutions. The fund's focus on health science enterprises positions it to capture the value generated by this shift towards telemedicine.
• Growth opportunity 5: The global health and wellness market is expected to grow to $4.24 trillion by 2026, driven by a rising consumer focus on health. LOGSX can tap into this trend by investing in health tech companies that provide innovative solutions for wellness and preventive care. This growing market offers the fund a unique opportunity to diversify its investments while aligning with consumer preferences.

What Are LOGSX's Competitive Advantages?

• Focused investment strategy in the rapidly growing healthcare sector.
• Strong research capabilities to identify high-potential investment opportunities.
• Established track record of adapting to market changes and investor needs.
• Flexibility to invest in various equity types enhances portfolio diversification.
• Defensive nature of healthcare investments provides stability during market downturns.

What Does LOGSX Do?

Live Oak Health Sciences Fund (LOGSX) was established to provide investors with exposure to the dynamic healthcare sector, which includes pharmaceuticals, biotechnology, and medical devices. The fund primarily invests in common stocks of companies engaged in the research, development, manufacturing, or distribution of healthcare-related products and services. Maintaining a disciplined investment approach, LOGSX allocates at least 80% of its net assets to equity investments in health science enterprises, ensuring a robust portfolio aligned with the sector's growth trajectory. While the fund primarily emphasizes U.S. companies, it retains the flexibility to diversify its investments by including equity REITs, foreign company shares, and American Depositary Receipts, provided they meet the fund's established investment criteria. Over the years, the fund has evolved to adapt to changing market conditions and investor needs, positioning itself as a key player in the asset management industry. Its focus on the healthcare sector capitalizes on the increasing demand for innovative medical solutions and the ongoing advancements in life sciences, making it a noteworthy option for investors seeking growth in a defensive sector. The fund's strategy is underpinned by a commitment to rigorous research and analysis, enabling it to identify high-potential investment opportunities within the healthcare landscape.

What Products and Services Does LOGSX Offer?

• Invest primarily in common stocks of healthcare-related companies.
• Focus on businesses involved in research, development, manufacturing, or distribution of medical products.
• Allocate at least 80% of net assets to equity investments in health sciences.
• Maintain flexibility to invest in equity REITs and foreign shares.
• Conduct rigorous research to identify high-potential investment opportunities.
• Adapt investment strategies based on market conditions and trends.

How Does LOGSX Make Money?

• Generate returns through capital appreciation of equity investments in health sciences.
• Leverage a diversified portfolio to mitigate risks associated with individual investments.
• Utilize a disciplined investment approach to focus on high-growth sectors within healthcare.
• Engage in active management to optimize portfolio performance.
• Monitor regulatory and market developments to inform investment decisions.

What Industry Does LOGSX Operate In?

The asset management industry is increasingly focused on niche sectors, with healthcare being a prominent area of growth. The competitive landscape includes various mutual funds and ETFs targeting healthcare investments, but LOGSX differentiates itself through its concentrated focus on U.S. health science equities. The ongoing advancements in biotechnology and pharmaceuticals, combined with an aging population, create a favorable environment for growth, making healthcare a resilient sector even during economic downturns.

Who Are LOGSX's Key Customers?

• Institutional investors seeking exposure to healthcare sector growth.
• High-net-worth individuals looking for diversified investment options.
• Financial advisors managing client portfolios with a focus on health sciences.
• Retirement funds aiming for long-term capital appreciation.
• Wealth management firms interested in sector-specific mutual funds.

Live Oak Health Sciences Fund (LOGSX) Valuation Context

Valued at $54.6M, LOGSX is classified as a micro-cap stock. Relative to its peer group, LOGSX's quantitative score of 47/100 is below the peer average of 57/100.

Return on equity for Live Oak Health Sciences Fund stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 0.0%, showing how much profit it generates from its asset base. LOGSX trades at a trailing price-to-earnings ratio of 0.00, below the Financial Services sector average of ~18x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.00 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

LOGSX Financials

LOGSX Latest News

No recent news available for LOGSX.

LOGSX Analyst Consensus

LOGSX MoonshotScore

Live Oak Health Sciences Fund Financial Services Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources